Biovian Oy. (9/22/22). "Press Release: Biovian Announces the Appointment of a New Board Member. Dr. Uwe Gottschalk Has Joined Biovian’s Board of Directors".

	Organisation	Biovian Oy
	Organisation 2	Keensight Capital SAS
	Product	contract manufacturing (biologicals)
	Product 2	private equity
	Person	Gottschalk, Uwe (Keensight Capital 202201– Operating Partner before Lonza + Sartorius + Bayer)
	Person 2	Rémy, Pierre (Keensight Capital 201907 Managing Partner)

Biovian, a Nordic Bio-CDMO committed to providing premium One-Stop-Shop GMP services to biotech companies, is delighted to announce that Dr. Uwe Gottschalk has been elected to its Board of Directors.

Uwe has a strong experience within the field of biotechnology. He has been awarded the Bioprocessing Lifetime Achievement Award (2021) and holds a Ph.D. in Chemistry from the University of Münster. From January 2022 onwards, he has supported Keensight Capital as Operating Partner. Before joining Keensight Capital, Uwe was the Chief Scientific Officer (2017-2022) and Chief Technology Officer (2014-2017) of Lonza Pharma. Prior to joining Lonza, Uwe served as the Vice President of Purification Technologies (2001-2009) and as Group Vice President (2009-2014) at Sartorius. He is also the former Head of Protein Purification at Bayer where he served from 1991 to 2004.

Pierre Remy, Chairman of the Board
“At Keensight, we are very pleased to welcome Uwe to the Board of Biovian. With his deep sector expertise, his decades of experience as well as his extremely well-connected network, Uwe will be able to accompany Biovian on its growth journey and help to further refine the strategy for the years to come.”

Dr. Uwe Gottschalk, Member of the Board
“I am very grateful for the opportunity to support Biovian on its dynamic path to the future of biomanufacturing. With the existing client base, talent pool, and technology platforms Biovian has the perfect mix for continued success across many therapeutic modalities.”

About Biovian

Biovian is a CDMO that provides premium services to biotech companies developing innovative gene therapies or biopharmaceuticals. Biovian offers its clients a One-Stop-Shop GMP CDMO service, with modularity available from gene to finished vial. Biovian is especially focusing on Viral Vector production, microbial production of recombinant proteins, and GMP plasmid DNA. Guided by its Nordic ethos Biovian has established a reputation for delivering high-quality work on time and within budget to a global client base. Additional information is available at https://biovian.com/

Communication Contact:

Taru Värri, Marketing Manager
+358 50 3650973 / [email protected]

Record changed: 2024-01-06